Altimmune, Inc.
NGM: ALTLive Quote
📈 ZcoreAI Score
Our AI model analyzes Altimmune, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get ALT Z-Score →About Altimmune, Inc.
Healthcare
Biotechnology
Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.
📊 Fundamental Analysis
Altimmune, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
The company recently reported 420.0% revenue growth, which is well above average for the Healthcare sector.
Return on Equity (ROE) is -50.6%, which indicates that capital utilization is currently under pressure.
At a current price of $3.24, ALT currently trades near the bottom of its 52-week range (8%), indicating potential value or weakness (Range: $2.87 - $7.73).
🏥 Financial Health
🔴
Profit Margin
Weak
✅
Debt/Equity
Excellent
✅
Revenue Growth
Excellent
🔴
Return on Equity
Weak
✅
Beta (Risk)
Low Volatility
Key Financials
Market Cap
$421.54M
Trailing P/E
--
Forward P/E
-2.37
Beta (5Y)
0.34
52W High
$7.73
52W Low
$2.87
Avg Volume
3.96M
Day High
Day Low